AN INHALABLE DRY POWDER FORMULATION COMPRISING GLP-1 FOR USE IN THE TREATMENT OF HYPERGLYCEMIA AND DIABETES BY PULMONARY ADMINISTRATION

摘要

A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.